Jerry Wu, PhD

Where You Are:
Jerry Wu, PhD

Senior Member

Office  (813) 745-6713

Education And Training
  • Fellow, University of Virginia Health Sciences Center, Charlottesville, Virginia, 1994 - Medicine & Pharmacology
  • Fellow, Memorial Sloan-Kettering Cancer Center, 1990 - Molecular Biology
  • PhD, University of Kansas Medical Center, Kansas City, Kansas, 1988 - Biochemistry
  • BS, Xiamen University, Xiamen, China, 1982 - Biology


The long-term goals of my laboratory are to reveal the signal transduction mechanisms that control cell proliferation, differentiation, survival, and motility and to explore key signaling molecules as targets for cancer therapy. We are interested in understanding fundamental cell signaling mechanisms that regulate cellular responses to extracellular cues as well as abnormal signal transduction pathways that mediate malignant growth and metastasis. Our research areas include ErbB, Src, and Bcr-Abl tyrosine kinases, Gab family docking proteins, SHP1 and SHP2 tyrosine phosphatases, MAP kinases, lysophosphatidic acid, and molecular chaperones. Over the last several years, the lab has been focused characterizing the regulation and function of Shp2 in growth factor signaling and oncogenesisWe are particularly interested in breast cancer, prostate cancer, and leukemia. Multidisciplinary approaches of molecular biology, biochemistry, cell biology, immunology, and bioinformatics are routinely used in our studies.

  • Schneeberger VE, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, Wu J. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014 Aug;35(8):1717-1725. Pubmedid: 24480804.
  • Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013 Oct;3:3042. Pubmedid: 24154688.
  • Win-Piazza H, Schneeberger VE, Chen L, Pernazza D, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Lett. 2012 Jul;320(1):81-85. Pubmedid: 22306001. Pmcid: PMC3319810.
  • Pagán B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol. 2011 Nov;17(44):4858-4866. Pubmedid: 22171126. Pmcid: PMC3235628.
  • Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U, Li P, Hann S, Nicosia SV, Wu J, Zhang X, Bai W. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol. 2011 May;338(1-2):58-67. Pubmedid: 21458521. Pmcid: PMC3089697.
  • Fragale A, Stellacci E, Ilari R, Remoli AL, Lanciotti A, Perrotti E, Shytaj I, Orsatti R, Lawrence HR, Lawrence NJ, Wu J, Rehli M, Ozato K, Battistini A. Critical role of IRF-8 in negative regulation of TLR3 expression by Src homology 2 domain-containing protein tyrosine phosphatase-2 activity in human myeloid dendritic cells. J Immunol. 2011 Feb;186(4):1951-1962. Pubmedid: 21220691. Pmcid: PMC4053178.
  • Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg Med Chem Lett. 2011 Jan;21(2):730-733. Pubmedid: 21193311. Pmcid: PMC3034307.
  • Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, Koomen JM, Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer. 2010 Oct;1(10):994-1007. Pubmedid: 21442024.
  • Pagán B, Isidro AA, Coppola D, Chen Z, Ren Y, Wu J, Appleyard CB. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res. 2010 Sep;30(9):3345-3353. Pubmedid: 20944107. Pmcid: PMC3733557.
  • Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem Pharmacol. 2010 Sep;80(6):801-810. Pubmedid: 20510203. Pmcid: PMC2906681.
  • Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des. 2010 Jun;16(16):1843-1862. Pubmedid: 20337577. Pmcid: PMC3076191.
  • Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T, Wu J, Wang HG. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J Biol Chem. 2008 Jul;283(27):19112-19118. Pubmedid: 18474606. Pmcid: PMC2441553.
  • Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol. 2006 Aug;70(2):562-570. Pubmedid: 16717135.
  • Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005 Sep;4(9):1311-1319. Pubmedid: 16170022.
  • Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood. 2005 Feb;105(3):1246-1255. Pubmedid: 15388581.
  • Kong X, San Juan H, Behera A, Peeples ME, Wu J, Lockey RF, Mohapatra SS. ERK-1/2 activity is required for efficient RSV infection. FEBS Lett. 2004;559(1-3):33-38. Pubmedid: 14960303.
  • Gyory I, Wu J, Fejer G, Seto E, Wright K. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol. 2004;5(3):299-308. Pubmedid: 14985713.
  • Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 Aug;63(16):5126-5135. Pubmedid: 12941844.
  • Ren Y, Wu J. Simultaneous suppression of Erk and Akt/PKB activation by a Gab1 pleckstrin homology (PH) domain decoy. Anticancer Res. 2003;23(4):3231-3236. Pubmedid: 12926057.
  • Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec;21(57):8804-8816. Pubmedid: 12483533.
  • Yang J, Kim O, Wu J, Qiu Y. Interaction between tyrosine kinase Etk and RUN domain- and FYVE domain-containing protein RUFY1. A possible role of Etk in regulation of vesicle trafficking. J Biol Chem. 2002;277(33):30219-30226. Pubmedid: 11877430.
  • Kim S, Loesch K, Wang X, Jiang J, Mei L, Cunnick J, Wu J, Frank S. A role for Grb2-associated binder-1 growth hormone signaling. Endocrinology. 2002;143(12):4856-4867. Pubmedid: 12446613.
  • Dorsey J, Cunnick J, Mane S, Wu J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of the Bcr-Abl(+) K562 cells by Gab2. Blood. 2001;99(4):1388-1397. Pubmedid: 11830491.
  • Cunnick J, Mei L, Doupnik C, Wu J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem. 2001;276(26):24380-24387. Pubmedid: 11323411.
  • Cunnick J, Dorsey J, Munoz-Antonia T, Mei T, Wu J. Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation response to lysophosphatic acid and epidermal growth factor. J Biol Chem. 2000;275(18):13842-13848. Pubmedid: 10788507.
  • Sekharam M, Cunnick J, Wu J. Involvement of lipoxygenase in lysophosphatidic acid-stimulated hydrogen peroxide release in human HaCaT keratinocytes. Biochem J. 2000;346(Pt 3):751-758. Pubmedid: 10698703.
  • Dorsey J, Jove R, Kraker A, Wu J. The pyrido [2,3-d] pyrimidine derivative PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000;60(12):3127-3131. Pubmedid: 10866298.
  • Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. 1999 Nov;19(11):7519-7528. Pubmedid: 10523640. Pmcid: PMC84756.
  • Yu R, Lei W, Mandlekar S, Weber M, Der C, Wu J, Kong A. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem. 1999;274:27545-27552. Pubmedid: 10488090.
  • Cunnick J, Dorsey J, Standley T, Turkson J, Kraker A, Fry D, Jove R, Wu J. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem. 1998;273(23):14468-14475. Pubmedid: 9603960.
  • Cunnick J, Dorsey J, Mei L, Wu J. Reversible regulation of SHP-1 tyrosine phosphatase activity by oxidation. Biochem Mol Biol Int. 1998;45:887-894. Pubmedid: 9739453.
  • Liu R, Fan C, Mitchell S, Chen Q, Wu J, Zuckerman K. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line mo7e. Cancer Res. 1998;58(10):2217-2223. Pubmedid: 9605769.
  • Sekharam M, Trotti, III A, Cunnick J, Wu J. Supression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998;149:210-216. Pubmedid: 9571990.
  • Hu X, Moscinski L, Hill B, Chen Q, Wu J, Fisher A, Zuckerman K. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk Res. 1998;22:817-826. Pubmedid: 9716013.
  • Stofega M, Yu C, Wu J, Jove R. Activation of extracellular signal-regulated kinase (ERK) by mitogenic stimuli is repressed in v-Src-transformed cells. Cell Growth Differ. 1997;8:113-119. Pubmedid: 8993840.
  • Rani C, Wang F, Fuior E, Burger A, Wu J, Sturgill T, Beitner-Johnson, LeRoith D, Varticovski L, Spiegel S. Divergence in signal transduction pathways of PDGF and EGF receptors: involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. J Biol Chem. 1997;272:10777-10783. Pubmedid: 9099730.
  • Chen Q, Olashaw N, Wu J. Participation of reactive oxygen species in the lysophos phatidic acid-stimulated mitogen-activated protein kinase activation pathway. J Biol Chem. 1995;270:28499-28502. Pubmedid: 7499358.
  • Wu J, Spiegel S, Sturgill T. Sphingosine-1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G-protein dependent mechanism. J Biol Chem. 1995;270:11484-11488. Pubmedid: 7744787.
  • Wu J, Lau L, Sturgill T. Rapid deactiviation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP-1. Febs Lett. 1994;353:9-12.
  • Dent P, Chow Y, Wu J, Morrison D, Jove R, Sturgill T. Expression, purification and characterization of recombinant mitogen-activated protein kinase kinases. Biochem J. 1994;303:105-112.
  • Aziz N, Wu J, Dubendorff J, Lipsick J, Sturgill T, Bender T. C-myb and v-myb are differentially phosphorylated by p42(mapk) in vitro. Oncogene. 1993;8:2259-2265.
  • Dent P, Wu J, Romero G, Vinvent L, Castle D, Sturgill T. Activation of the mitogen-activated protein kinase pathway in Triton X-100 disrupted NIH-3T3 cells by p21 ras and in vitro by plasma membranes from NIH3T3 cells. Mol Biol Cell. 1993;4:484-493.
  • Wu J, Harrison J, Dent P, Lynch K, Weber M, Sturgill T. Identification and characterization of a new mammalian MAP kinase kinase: MKK2. Mol Cell Biol. 1993;13:4539-4548.
  • Wu J, Michel H, Den P, Haystead T, Hunt D, Sturgill T. Activiation of MAP kinase by a dual specificity Thy/Thr kinase. Adv Second Messenger Phosphoprotein Res. 1993;28:219-225.
  • Haystead C, Wu J, Sturgill T, Haystead T. Functional expression of a MAP kinase kinase in COS cells and recognition by an anti-STE7/byrl antibody. Febs Lett. 1993;317:12-16.
  • Wu J, Harrison J, Vincent L, Haystead C, Haystead T, Michel H, Hunt D, Lynch K, Sturgill T. Molecular structure of a protein tyrosine/threonine kinase activating p42 mitogen-activated protein (MAP) kinase: MAP kinase kinase. Proc Natl Acad Sci U S A. 1993;90:173-177.
  • Wu J, Dent P, Jelinek T, Wolfman A, Weber M, Sturgill T. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3', 5'-monophosphate. Science. 1993;262:1065-1069.
  • Wu J, Michel H, Rossomando A, Haystead T, Shabanowitz J, Hunt D, Sturgill T. Renaturation and partial peptide sequencing of mitogen activated protein (MAP) kinase activator from rabbit skeletal muscle. Biochem J. 1992;285:701-705.
  • L'Allemain G, Her J, Wu J, Sturgill T, Weber M. Growth factor induce activation of a kinase activity which causes regulatory phosphorylation of p42/microtubule-associated protein kinase. Mol Cell Biol. 1992;12:2222-2229.
  • Rossomando A, Wu J, Weber M, Sturgill T. The phorbol ester-dependent activiation of p42(mapk) is a kinase(s) with specificity for the THr and Tyr regulatory sites. Proc Natl Acad Sci U S A. 1992;89:5221-5225.
  • Haystead T, Dent P, Wu J, Haystead C, Sturgill T. Ordered phosphorylation of p42(mapk) by MAP kinase kinase. Febs Lett. 1992;306:17-22.
  • Nakielny S, Cohen P, Wu J, Sturgill T. MAP kinase activator from insulin-stimulated skeletal muscle is a protein threonine/tyrosine kinase. Embo J. 1992;11:2123-2129.
  • Rossomando A, Wu J, Michel H, Shabanowitz J, Hunt D, Weber M, Sturgill T. Identification of Tyr185 as the site of tyrosine autophosphorylation of recombinant pp42/mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1992;89:5779-5783.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions